Pediatric Down Syndrome Upper Airway Stimulation: Patient Selection and Post‐Implantation Optimization

Abstract

AbstractObjectiveThe Food and Drug Administration recently approved upper airway stimulation (UAS) for children with Down Syndrome and persistent obstructive sleep apnea who meet certain inclusion and exclusion criteria. Although there is a robust experience with this therapy in the adult population, established protocols used in adults are not directly transferrable to a complex pediatric population. This review aims to combine the protocols from several institutions for patient selection and postimplantation optimization, including a protocol for Drug‐Induced Sleep Endoscopy in children with Down Syndrome, preactivation threshold measurements, device titration, and follow‐up sleep studies.Study DesignExpert panel development of best Practice algorithm.SettingMulti‐institutional investigator review.MethodsAn expert panel was assembled of pediatric otolaryngologists with extensive experience in hypoglossal nerve stimulation in children with Down Syndrome. Thirty statements were created during an initial drafting session. A modified Delphi method was used assess consensus among the panel.ResultsAfter 2 rounds of Delphi surveys, 29 statements met criteria for consensus. One statement did not meet consensus. The statements were grouped into several categories to facilitate presentation.ConclusionsA standardized approach to UAS for children with Down Syndrome must take into account the unique challenges inherent to treating a complex pediatric population with a high rate of sensory processing disorders. This expert panel has met consensus on several statements that will guide clinicians as this novel therapy is adopted.